Table 1 The clinicopathological variables in patients with HCC (n = 217).
Variables | N = 217 |
|---|---|
Age (years), mean (SD) | 50.12 (12.7) |
Albumin (g/L), mean (SD) | 41.36 (4.36) |
WBC (109/L), mean (SD) | 5.33 (1.78) |
Neutrophil (109/L), mean (SD) | 3.26 (1.23) |
Lymphocyte (109/L), mean (SD) | 1.44 (0.50) |
Monocyte (109/L), mean (SD) | 0.45 (0.18) |
PLT (109/L), mean (SD) | 152.37 (66.82) |
Total bilirubin (μmol/L), mean (SD) | 13.05 (5.78) |
Direct bilirubin (μmol/L), mean (SD) | 6.10 (2.79) |
ALBI (μmol/g), mean (SD) | − 2.81 (0.37) |
ALT (U/L), mean (SD) | 43.08 (46.09) |
AST (U/L), mean (SD) | 45.94 (32.94) |
PT (s), mean (SD) | 13.92 (1.34) |
ATPP (s), mean (SD) | 35.13 (4.13) |
Tumor diameter (cm), mean (SD) | 5.93 (3.47) |
TBS, mean (SD) | 6.10 (3.40) |
TTV, mean (SD) | 242.73 (423.90) |
SII, mean (SD) | 389.09 (299.60) |
PLR, mean (SD) | 114.05 (54.72) |
MLR, mean (SD) | 0.33 (0.16) |
NLR, mean (SD) | 2.50 (1.57) |
Gender | |
male | 191 (88.02%) |
female | 26 (11.98%) |
HBV | |
Presence | 194 (89.40%) |
Absence | 23 (10.60%) |
Antiviral therapy | |
Yes | 47 (21.66%) |
No | 170 (78.34%) |
CSPH | |
Yes | 41 (18.89%) |
No | 176 (81.11%) |
ALBI grade | |
I | 56 (25.82%) |
II | 161 (74.18%) |
HBV-DNA | |
≥ 1000 c | 119 (54.84%) |
< 1000 c | 98 (45.16%) |
AFP | |
≥ 400 ng/mL | 67 (30.88%) |
< 400 | 150 (69.12%) |
Tumor number | |
Single | 184 (84.79%) |
Multiple | 33 (15.21%) |
Degree of differentiation | |
High and middle | 178 (82.03%) |
Low | 39 (17.97%) |
Satellite nodules | |
Yes | 162 (74.65%) |
No | 55 (25.35%) |
MVI | |
Yes | 108 (49.77%) |
No | 109 (50.23%) |
Cirrhosis | |
Yes | 168 (77.42%) |
No | 49 (22.58%) |
BCLC stage | |
0-A | 172 (79.26%) |
B-C | 45 (20.74%) |
Median follow-up period (SD, month) | 21.32 (14.40) |
Relapsed | 127 |
Within 2 years | 111 |
Beyond 2 years | 16 |
Intrahepatic metastasis | 117 |
Extrahepatic metastasis | 10 |
No relapsed | 90 |
